
Celltrion Pharm Reports Increased Q3 Profit Driven by Higher Revenues
Celltrion Pharm has announced a substantial rise in its profits and revenues for the third quarter.
Celltrion Pharm has announced a substantial rise in its profits and revenues for the third quarter.
Celltrion Pharm Inc. has reported a significant increase in its profits for the third quarter of the year. The South Korean pharmaceutical company saw its profit soar to 17.671 billion Korean won, up from 11.459 billion won in the same period last year.
Earnings per share also rose, climbing to 399 won compared to 259 won a year ago. The company’s operating income reached 23.901 billion won, a notable increase from the previous year's 16.108 billion won.
In terms of revenue, Celltrion Pharm reported 161.874 billion won for the quarter, which is an increase from 138.175 billion won in the previous year. This growth reflects the company's strong financial performance and its ability to capitalize on market opportunities.
Despite these positive results, shares of Celltrion Pharm traded down by 1.70 percent on the KOSDAQ, indicating mixed market reactions to the earnings report. Investors will be keen to see how the company continues to perform in the upcoming quarters.
Related companies
Where it matters
Related coverage

Celltrion Wins Brazil Cancer Drug Tender for Seventh Straight Year
Samsung Biologics Completes 2.7 Trillion Won Rights Offering

Celltrion Launches Three New Biosimilars in Brazil
